A phase II, randomized-double, active-controlled, dose-finding clinical study that evaluated the safety, tolerability, and immunogenicity of the investigational vaccine, VAX-31, in healthy infants. Participants were given four doses at two, four, six, and 12-15 months of age, alongside routine pediatric vaccines.